Arcellx is a clinical-stage biotechnology company based in Gaithersburg, Maryland, dedicated to developing innovative cell therapies for cancer and other challenging diseases. Founded in 2014, the company focuses on creating safer and more effective treatments through its proprietary technologies. Arcellx went public on NASDAQ in 2021, raising funds to support its clinical trials and research initiatives.

The company's core technology is the D-Domain binding scaffold, which allows for precise control over engineered T cells. This innovation supports their ARC-SparX platform, enabling the development of controllable cell therapies. Arcellx's lead product candidates include anitocabtagene autoleucel (ACGT-002) and ACLX-001, both targeting multiple myeloma and currently in clinical trials. The company collaborates with academic institutions to enhance its research and aims to address critical unmet needs in oncology, particularly for patients with relapsed or refractory multiple myeloma.